Chapter 4 - THE COMPANY HE NEEDED ME TO LOSE
Daniel was discharged the following afternoon.
He went to a hotel near North Hills.
Not home.
Not to Celeste.
His lawyer sent Marissa a message saying Daniel feared for his safety.
I read it twice.
Then handed my phone back.
“He fears me.”
“He fears the narrative he created collapsing,” Marissa said.
We were sitting in my mother’s kitchen in Apex.
I had refused to stay in our house until police released it.
Mom had changed nothing since I was twenty.
Same oak table.
Same blue ceramic fruit bowl.
Same refrigerator magnets from vacations we could barely afford when I was a child.
The familiarity helped.
“Can he actually convince people I did this?”
“He doesn’t need to convince everyone.”
“How comforting.”
“He needs reasonable doubt around his own conduct.”
My phone buzzed.
An email from Veyron.
Special shareholder meeting.
Three days away.
Purpose:
Review of pending strategic transaction and interim leadership authority.
I looked at Marissa.
“Strategic transaction.”
She read it.
“You knew about a sale?”
“No.”
“Maybe now we know why timing mattered.”
We called Arthur Keene.
He resisted for seven minutes.
Then Marissa reminded him I owned thirty-two percent of voting shares.
He gave us the outline.
Veyron had spent four months negotiating an acquisition by a Boston pharmaceutical company called Haldane Therapeutics.
Indicative value:
$186 million.
Closing depended on two things.
Clear patent ownership.
And approval from both founders whose signatures appeared on the original core licensing agreement.
Daniel.
And me.
“I never agreed to sell,” I said.
“You weren’t formally presented the offer yet,” Arthur said.
“When was that supposed to happen?”
“Next month.”
“After what?”
Silence.
“Arthur.”
“After confirmatory due diligence.”
“What exactly is wrong with the patent chain?”
Another pause.
Marissa leaned toward the speaker.
“Mr. Keene, answer carefully.”
Arthur sighed.
“Mara’s original inventorship contribution is greater than the public patent history reflects.”
I laughed.
“That is a very expensive way of saying Daniel erased me.”
“We were working to correct inventorship.”
“Without telling me?”
“Counsel believed it could be handled internally.”
“By whom?”
“Daniel.”
“Of course.”
Marissa said, “Why does Mara’s present competence matter?”
Arthur did not answer immediately.
I already knew.
Our shareholders agreement contained a medical-incapacity clause.
We had added it when Veyron was tiny and one founder spent six months undergoing cancer treatment.
If a founder was medically unable to act for thirty consecutive days, temporary voting authority transferred to a designated proxy.
Mine was Daniel.
I had never changed it.
Because once, I trusted him.
Marissa said, “You were planning to use that clause.”
Arthur’s voice hardened.
“We were not planning anything.”
“Daniel was.”
“We cannot speak for him.”
I asked, “When was Haldane told I might be medically unavailable?”
Silence.
That silence answered me.
“When?”
Arthur finally said, “Last week.”
My hand tightened around the edge of the table.
“Who told them?”
“Daniel.”
“What did he say?”
“That you were experiencing recurring neurological symptoms and may require evaluation.”
I stared at the wall.
Before the marks.
Before Daniel accidentally slept on the treated surface.
Before I had any symptoms at all.
“He already told the buyer I was sick.”
“Yes.”
Marissa asked, “Did anyone verify that?”
“No.”
“Did Celeste know?”
“She chairs the strategy committee.”
Of course she knew.
The life-insurance policy.
The sleeping questions.
The mattress.
The photos.
The planned corporate sale.
The pieces no longer looked random.
But the motive had shifted.
Maybe Daniel did not need me dead.
Maybe he needed me unavailable.
For thirty days.
Long enough to sign the deal.
Long enough to lock in a sale.
Long enough for whatever chemical exposure he arranged to become a medical record instead of a crime.
I asked Arthur, “If I had become medically incapacitated, could Daniel approve the sale for me?”
“Temporarily, yes.”
“And after closing?”
“The agreement would be binding.”
Marissa muted the call.
“This is motive.”
I nodded.
“But not the life insurance.”
“No.”
“And not Celeste.”
“No.”
When we unmuted, I asked for every document relating to the Haldane transaction.
Arthur refused.
Marissa threatened immediate court action on shareholder-access grounds.
He compromised.
We received a secure data-room invitation that afternoon.
I spent six hours reading.
Not because I should have.
Because I could not stop.
Veyron had cash problems.
Serious ones.
A failed manufacturing expansion.
A delayed FDA submission.
Two key investors refusing additional capital.
Without the Haldane sale, the company might need layoffs and emergency financing.
Daniel stood to receive roughly $28 million before taxes.
My stake was worth approximately $31 million.
Celeste’s trust held enough founder shares to receive nearly $14 million.
I understood the desperation now.
But desperation did not explain why Celeste photographed me sleeping.
At eleven that night, I found an email from Haldane’s counsel.
To Daniel.
Copied to Celeste.
Subject:
Founder Consent Risk.
The message said Haldane would not proceed without either my signature or documented invocation of the incapacity clause.
Daniel replied:
We expect medical documentation shortly.
Celeste replied eight minutes later:
She won’t obstruct us after August.
I read that sentence until my vision blurred.
After August.
Not after the shareholder meeting.
Not after counseling.
Not after negotiations.
After August.
Marissa read it over my shoulder.
“This is worse.”
“Yes.”
My phone rang.
Unknown number.
I answered.
“Mara?”
Lena.
“You shouldn’t be calling me.”
“I know.”
“Then why are you?”
“Because I found out what VX-17 was supposed to be.”
I stood.
“Supposed to be?”
“Yes.”
“What does that mean?”
“The formulation Daniel requested was not what was found in his blood.”
My skin prickled.
“What did he request?”
“A short-duration sedative from an abandoned Veyron series. The whole point was reversibility.”
“You expect that to make me feel better?”
“No.”
“Then what was in Daniel?”
“I don’t know the final identity. But it came from a different preclinical family.”
“How different?”
Lena’s breathing sounded shallow.
“The batch Daniel authorized shouldn’t have caused the cardiovascular effect he had.”
I looked at Marissa.
She could hear Lena through the speaker.
“Who changed it?” I asked.
“I don’t know.”
“You have access logs.”
“I found one.”
“One what?”
“A formulation revision.”
“Signed by whom?”
“That’s the problem.”
“Lena.”
“It wasn’t signed.”
“Then how do you know it exists?”
“Because someone deleted it.”
I closed my eyes.
“How did you recover it?”
“Automatic equipment backup.”
“What did the revision do?”
“I’m not giving technical details.”
“Good.”
Lena swallowed.
“It substituted the active formulation.”
“Who had access to do that?”
“Three people.”
“Name them.”
“One was Daniel.”
“Second?”
“Dr. Peter Hsu, formulation lead.”
“And third?”
Silence.
“Lena.”
“Celeste.”
I almost laughed.
“She isn’t a scientist.”
“She doesn’t need to be to approve a stored formulation and send it to the automated dispenser.”
“Would she know what it did?”
“If someone told her.”
“Who?”
“I don’t know.”
The line crackled.
Then Lena whispered, “Mara, there’s something else.”
“What?”
“The reformulation happened after Daniel’s final approval.”
“When?”
“Twenty-two minutes later.”
Daniel ordered one drug.
May you like
Someone changed it after he signed off.
And the person with the clearest unexplained access was his mother.
Related Stories
